当前位置: X-MOL 学术J. Antimicrob. Chemother. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2020-08-19 , DOI: 10.1093/jac/dkaa331
Gholamali Eslami 1 , Sajedeh Mousaviasl 1 , Esmat Radmanesh 1 , Saeed Jelvay 1 , Saeid Bitaraf 2 , Bryony Simmons 3 , Hannah Wentzel 3 , Andrew Hill 4 , Anahita Sadeghi 5 , James Freeman 6 , Shokrollah Salmanzadeh 7 , Hani Esmaeilian 1 , Morteza Mobarak 1 , Ramin Tabibi 1 , Amir Hosein Jafari Kashi 1 , Zahra Lotfi 1 , Seyed Mehdi Talebzadeh 1 , Aseni Wickramatillake 8 , Mahboobeh Momtazan 1 , Majid Hajizadeh Farsani 1 , Sedigheh Marjani 1 , Sara Mobarak 1
Affiliation  

Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19.

中文翻译:

索磷布韦/达卡他韦或利巴韦林对重症 COVID-19 患者的影响。

索磷布韦和达卡他韦是直接作用的抗病毒药物,对丙型肝炎病毒非常有效。一些计算机体外证据表明这些药物也可能对 SARS-CoV-2 有效。该试验评估了索磷布韦联合达卡他韦治疗 COVID-19 患者的有效性。
更新日期:2020-10-17
down
wechat
bug